Dror Bashan
Net Worth
Last updated:
What is Dror Bashan net worth?
The estimated net worth of Mr. Dror Bashan is at least $1,976,242 as of 19 Oct 2023. He owns shares worth $178,072 as insider and has received compensation worth at least $1,798,170 in Protalix BioTherapeutics, Inc..
What is the salary of Dror Bashan?
Mr. Dror Bashan salary is $599,390 per year as Pres, Chief Executive Officer & Director in Protalix BioTherapeutics, Inc..
How old is Dror Bashan?
Mr. Dror Bashan is 58 years old, born in 1967.
What stocks does Dror Bashan currently own?
As insider, Mr. Dror Bashan owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | Pres, Chief Executive Officer & Director | 116,387 | $1.53 | $178,072 |
What does Protalix BioTherapeutics, Inc. do?
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Dror Bashan insider trading
Protalix BioTherapeutics key executives
Protalix BioTherapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Einat Brill-Almon (65) Senior Vice President & Chief Devel. Officer
- Mr. Dror Bashan (58) Pres, Chief Executive Officer & Director
- Mr. Eyal Rubin M.B.A. (49) Senior Vice President, Chief Financial Officer, Treasurer & Corporation Sec.